Skip to Content
U.S. National Institutes of Health
Last Updated: 01/06/14

S. Percy Ivy, MD
Associate Branch Chief, IDB

S. Percy Ivy, MD is the Associate Chief (2005) of the Investigational Drug Branch (IDB) which is part of the Cancer Therapy Evaluation Program (CTEP) in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute. She received her medical and subspecialty training at Tulane University Medical School, Vanderbilt University Medical Center and the National Cancer Institute, respectively. During her fellowship she worked in the Molecular Pharmacology Section which focused on the molecular mechanisms of drug resistance mediated by the ABC transporter genes in models of breast cancer and carcinogenesis. She is currently an Associate Professor of Pediatrics at the George Washington University School of Medicine on the faculty at Children’s National Medical Center where she attends in the leukemia clinic.

In her role as Associate Chief of IDB she supervises several Senior Investigators in the Experimental Therapeutics Section I with a focus on angiogenesis inhibitors, heat shock protein 90 inhibitors and inhibitors of receptor:ligand interactions including disregulated cancer stem cell embryonic signaling pathways for hedgehog, notch, wnt and others. She has received four NIH Merit Awards for her work on specialized studies in patients with hepatic and renal dysfunction using cancer investigational therapeutics, use of novel imaging techniques for the evaluation of investigational agents in early clinical trials and most recently for assisting the in the implementation of the Investigational Drug Steering Committee (IDSC) which is part of the Clinical Trials Working Group, an NCI initiative for improving NCI-sponsored clinical trials in the US. She serves on the IDSC coordination team as well as starting the angiogenesis task force and now chairing the Clinical Trial Design Task Force for Early Clinical Trials.

She serves on the Scientific Committee for the AACR-NCI-EORTC Molecular Targets Conference and for the Experimental Therapeutics Section for ASCO. She has presented both nationally and internationally on topics related to early therapeutics development, the role of anti-angiogenic agents in cancer therapy, clinical trials for patients with hepatic and renal dysfunction and on the experimental therapeutics program in CTEP.

She has published 64manuscripts and 7 book chapters in her areas of interest in experimental therapeutics. She has received the Margaret B. and Cyril A. Shulman Distinguished Service Award for starting the general pediatric clinic for medically indigent children at Bread for the City/Zaccheus Free Clinic and supports Doorways for women and children who are victims of abuse.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6565
Fax: 240-276-7894
E-mail: ivyp@ctep.nci.nih.gov